A Trial of Plerixafor/G-CSF as Additional Agents for Conditioning Before TCR Alpha/Beta Depleted HSCT in WAS Patients
A Trial of Plerixafor With G-CSF as Additional Agents in Conditioning Regimen for Prevention of Graft Failure After Transplantation With TCR Alpha/Beta Grafts Depletion in Patients With Wiskott-Aldrich Syndrome.
Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology
This PHASE2 trial investigates Graft Failure and Hematopoietic Stem Cell Transplantation and is currently ongoing. Federal Research Institute of Pediatric Hematology, Oncology and Immunology leads this study, which shows 7 recorded versions since 2016 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jan 2019 — Jan 2021 [monthly]
Recruiting PHASE2
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2019 [monthly]
Recruiting PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
Jun 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
For direct contact, visit the study record on ClinicalTrials.gov .